Adverts Drug Events on Outpatients Treated in the Nuclear Medicine and Oncology Center of Bach Mai Hospital via Clinical Pharmacist’s Active Surveillance

Abstract

Background: Despite significant advances in malignant neoplasms treatment and an increase of the survival in patients as a result of the chemotherapy using, a significant number of side effects, both immediate and delayed, significantly worsen the quality of life and often contribute to the development complications. Timely detection, monitoring, and control of the chemotherapy side effects are important in the algorithm for successful treatment and prevention of severe reactions in the human. The purpose of the study is to make survey of clinical characteristics of cancer patients treated by chemotherapy and adverse drug events (ADE) analysis via active surveillance of clinical pharmacist in the Nuclear medicine and oncology center.

Materials and Methods: We have analyzed data on the objective condition of patients and their medical files in August 2018. This is a discreptive cross-sectional study, ADE active surveillance without intervention.

Results: Ha been identified total 3.273 ADEs, in which 326/332 (98.2%), 259/332 (78.0%) patients had ADEs via interviewed and reviewed lab results, respectively. The most common ADEs were fatigue, appetite loss, anemia, leukopenia/neutropenia and ALAT/ASAT increased. The incidence and severity of ADE on each grades from 1 through 5 were 77.4%; 15.8%, 5.0%, 1.9% and 0%, respectively. The present study showed that the incidence of ADEs related to chemotherapy is very high.

Conclusions: Have been proved that active surveillance by clinical pharmacists in the Nuclear medicine and oncology center could effectively improve the quantity of ADEs. These active surveillance programs should be implemented usually in Nuclear medicine and Oncology hospitals to ensure patient safety.